One of the factors playing a part in the pathophysiology of heart failure (HF) with mid-range and preserved ejection fraction is assumed to be the build-up of epicardial adipose tissue (EAT). However, it is still not known what effect it has on the result. Cardiac magnetic resonance was used to calculate and assess the prognostic worth of EAT in the patients with HF with preserved ejection fraction and in the patients with HF with mid-range ejection fraction.
A potential multicenter study was conducted which had the main objective of scrutinizing the worth of loop-recorders that could be implanted in patients with HF with preserved ejection fraction and patients with mid-range ejection fraction. Cardiac magnetic resonance was used to measure the volume of EAT. A composite of first HF hospitalizations and all-cause mortality were the principal result. For every increase in SD in EAT, 95% CI and hazard ratios were described.
About 105 patients (mean age 72±8 years, 50% women, and mean left ventricular ejection fraction 53±8%) were examined. 31 patients either passed away or were hospitalized for heart failure during the median follow-up of 24 (17 to 25) months. EAT was vitally related with a higher danger of the composite result (HR, 1.76 [95% CI, 1.24–2.50], P=0.001) in the univariable investigation. Even after adjustments were made for gender, age, and body mass index (HR, 1.61 [95% CI, 1.13–2.31], P=0.009) as well as New York Heart Association functional class and N-terminal of pro-brain natriuretic peptide (HR, 1.53 [95% CI, 1.04–2.24], P=0.03), epicardial adipose tissue was still linked with the results. Additionally, there still remained a connection between EAT with HF hospitalizations alone (HR, 1.54 [95% CI, 1.04–2.30], P=0.03) and all-cause mortality alone (HR, 2.06 [95% CI, 1.26–3.37], P=0.004).
Patients with HF with preserved ejection fraction and HF with mid-range ejection fraction happen to have an unfavorable prognosis with the build-up of EAT. As such, this article highlights the significance of EAT in patients with heart failure.
Link:www.ahajournals.org/doi/10.1161/CIRCHEARTFAILURE.121.009238
